
This Wednesday was in many ways "just another day at the office" for Genmab Chief Executive Jan van de Winkel.
After leading the successful biotechnology company for more than ten years, the Dutch national, who in 2010 was described by some as a possible interim chief, is familiar with booking guidance upgrades and sending good news to shareholders.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app